IQVIA Holdings Inc. Q3 2026 Earnings Recap

IQVIA shares fell 0.7%, a broadly flat reaction, as the quarter showed improving organic growth and margin expansion alongside stronger clinical bookings. Management said revenue, EBITDA and adjusted EPS topped its guidance ranges, but the transcript does not establish how results compared with market expectations.

Key Takeaways

• Revenue grew 8% reported and 8.6% at constant currency; organic growth was approximately 6%.
• Adjusted EBITDA grew 8.7%, with margin expanding 20 basis points for a second consecutive quarter; adjusted diluted EPS rose 11.3%.
• Clinical revenue grew 8.7% reported, nearly 7% organically. Net new bookings reached $3.2 billion, up 15% year over year, while trailing 12-month bookings rose 14% to $11.7 billion.
• Commercial revenue grew 6.9% reported and 4% organically, double the prior-year organic growth rate; the company cited record pipeline levels.
• Management pointed to supportive demand indicators, including year-to-date clinical trial starts up high single digits and new drug launches up more than 40% year over year.